

1 **A new robust and accurate two-sample Mendelian randomization**
2 **method with a large number of genetic variants**

3 Lei Zhang^{1,2#*}, Jun-Jie Niu^{3#}, Xian-Mei He¹, Xiao Zheng¹, Qi-Gang Zhao⁴, Xiu-Juan Yu¹, Li

4 Luo⁵, Hai-Gang Ren^{2,6}, Yu-Fang Pei^{2,3*}

5 ¹Center for Genetic Epidemiology and Genomics, School of Public Health, Suzhou Medical College
6 of Soochow University, Jiangsu, 215123, PR China.

7 ²MOE Key Laboratory of Geriatric Diseases and Immunology, Soochow University, Suzhou, Jiangsu
8 215123, PR China.

9 ³Department of Orthopedic Surgery, the First Affiliated Hospital of Soochow University, Suzhou,
10 Jiangsu, 215006, PR China.

11 ⁴Department of Epidemiology and Biostatistics, School of Public Health, Suzhou Medical College of
12 Soochow University, Suzhou, Jiangsu, 215123, PR China.

13 ⁵School of Physical Education and Sport Science, Soochow University, Suzhou, 215021, PR China.

14 ⁶Laboratory of Molecular Neuropathology, Jiangsu Key Laboratory of Neuropsychiatric Diseases and
15 College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, PR China.

16 #: These authors contributed equally to this work.

17 * Corresponding authors

18 Lei Zhang, Ph. D

19 Professor

20 Center for Genetic Epidemiology and Genomics

21 School of Public Health, Suzhou Medical College of Soochow University

22 199 Ren-ai Rd., Suzhou City, Jiangsu Province 215123, PR China

23 Tel: (86) 0512-65883871 Email: lzhang6@suda.edu.cn

24 Yu-Fang Pei, Ph. D

25 Professor

26 Department of Epidemiology and Biostatistics

27 School of Public Health, Suzhou Medical College of Soochow University

28 199 Ren-ai Rd., Suzhou City, Jiangsu Province 215123, PR China

29 Tel: (86)0512-65880079 Email: ypei@suda.edu.cn

30

Abstract

31 Horizontal pleiotropy can significantly confound causal estimates in Mendelian
32 randomization (MR) studies, particularly when numerous instrumental variables (IVs) are
33 employed. In this study we propose a novel statistical method, Mendelian Randomization
34 analysis based on Z-scores (MRZ), to conduct robust and accurate MR analysis in the
35 presence of pleiotropy. MRZ models the IV-outcome association z-score as a mixture
36 distribution, separating the causal effect of the exposure on the outcome from pleiotropic
37 effects specific to each IV. By classifying IVs into distinct categories (valid, uncorrelated
38 pleiotropic, and correlated pleiotropic), MRZ constructs a likelihood function to estimate
39 both causal and pleiotropic effects. Simulation studies demonstrate MRZ's robustness, power,
40 and accuracy in identifying causal effects under diverse pleiotropic scenarios and overlapped
41 samples. In a bidirectional MR analysis of appendicular lean mass (ALM) and four lipid
42 traits using both the UK Biobank (UKB)-internal datasets and the UKB-Global Lipids
43 Genetics Consortium (GLGC) joint datasets, MRZ consistently identified a causal effect of
44 ALM on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). Conversely,
45 existing methods often detected mutual causal relationship between lipid traits and ALM,
46 highlighting their susceptibility to confounding by horizontal pleiotropy. A randomized
47 controlled experiment conducted in mice validated the absence of causal effect of TC on
48 ALM, corroborating the MRZ findings and further emphasizing its resilience against
49 pleiotropic biases.

50 **Keywords:** Mendelian randomization; uncorrelated pleiotropy; correlated pleiotropy;
51 appendicular lean mass; lipid traits.

52

Introduction

53 Determining whether a modifiable exposure causes a particular disease outcome is
54 crucial for understanding disease mechanisms and guiding prevention and clinical
55 interventions. However, traditional observational analyses often face limitations in
56 establishing such causal effects due to potential confounding by unobserved variables or
57 reverse causation [1]. Mendelian randomization (MR) provides a solution by offering a
58 statistical approach to infer causation from observational data while circumventing both
59 unobserved confounding and reverse causation [1, 2]. MR utilizes genetic variation associated
60 with an exposure as an instrumental variable (IV) to investigate the causal effect of the
61 exposure on an outcome [2].

62 MR has proven highly successful in uncovering causal relationships across a wide range
63 of epidemiological conditions and diseases, establishing itself as a popular approach in
64 modern genetic epidemiology [3]. The rapid growth of genome-wide association studies
65 (GWASs) further accelerates the application of MR by providing a wealth of data. With larger
66 sample sizes, modern GWASs generate numerous IVs suitable for MR analysis. For instance,
67 the latest human height GWAS identified over 11,000 independent association signals [4],
68 enhancing the power and accuracy of MR estimation.

69 However, many current MR analyses are challenged by a potentially severe confounding
70 factor known as horizontal pleiotropy [5]. Horizontal pleiotropy violates the exclusive
71 restriction assumption underlying the MR principle, casting doubt on the validity of MR
72 analysis [6-8]. This issue becomes more pronounced as the number of IVs increases, as
73 chance can lead to an increase in shared heritability factors between exposure and outcome.

74 Therefore, effective correction for confounding due to horizontal pleiotropy is essential,
75 especially in large sample settings.

76 Considerable efforts in the literature have addressed the pleiotropic effect and sought to
77 mitigate its adverse impact on MR analysis [9, 10]. In a two-sample setting, multiple popular
78 statistical methods accommodating pleiotropic IVs have been proposed and widely utilized
79 [11-37]. However, under certain conditions, some methods may fail to adequately correct for
80 horizontal pleiotropy or accurately detect true causal effects [9].

81 In this study, with the aim of conducting robust and accurate MR studies in the presence
82 of horizontal pleiotropy, we introduce a novel statistical method. This method explicitly
83 distinguishes causal effect from pleiotropic effect and estimates both within the maximum
84 likelihood framework. Through simulation studies, we demonstrate that our proposed method
85 effectively corrects for pleiotropic effects across various confounding scenarios while
86 maintaining statistical power at a comparable level. As an application, we investigate the
87 bidirectional causal effects of four lipid traits and appendicular lean mass (ALM) using data
88 from the UK biobank (UKB) cohort and summary statistics from the Global Lipids Genetics
89 Consortium (GLGC) [38]. Finally, we conduct a randomized controlled experiment in mice to
90 address controversial findings revealed by our proposed method compared to alternative
91 methods.

92

Results

93 Outline of the proposed method

94 The diagram illustrating the proposed method is presented in **Figure 1**. In this context,
95 we consider the causal effect, denoted as r , of a continuous exposure trait X on a continuous
96 outcome trait Y . Our objective is to estimate this causal effect using a collection of
97 independent IVs that exhibit an association with X . These IVs are categorized into three
98 distinct types based on their pleiotropic effects on the outcome and the correlation of these
99 pleiotropic effects with the IV-exposure effects at corresponding IVs:

100 1. Valid IVs: These IVs do not exert horizontal pleiotropic effects on the outcome. They
101 serve as reliable indicators of the exposure's effect on the outcome without introducing
102 additional confounding factors.

103 2. Uncorrelated pleiotropic IVs: This category comprises IVs that exhibit horizontal
104 pleiotropic effects on the outcome. However, these effects are not correlated with the
105 corresponding IV-exposure effects.

106 3. Correlated pleiotropic IVs: In this category, IVs demonstrate horizontal pleiotropic effects
107 on the outcome that are correlated with the IV-exposure effects. This correlation violates the
108 Instrument Strength Independent of Direct Effect (INSIDE) assumption [39].

109 In our analysis, we used genetic association z-scores, denoted as z_X and z_Y , to estimate r .
110 The outcome z_Y follows a normal distribution with a mean μ_Y and a variance of one,
111 i.e., $z_Y \sim N(\mu_Y, 1)$, where μ_Y represents the effect of the IV on the outcome. The causal
112 effect of X on Y can be interpreted as shifting the mean μ_Y by an IV-specific offset denoted

113 as $\Delta = \sqrt{\frac{N_Y}{N_X}} \times r z_X$, where N_X and N_Y are the sample sizes of the exposure and outcome,

114 respectively. Importantly, this shift applies uniformly across all IVs regardless of whether
115 they are valid or pleiotropic. Consequently, if we subtract this offset Δ from z_Y , we obtain a
116 residual z-score $z'_Y = z_Y - \Delta$. This residual z-score no longer contains any information
117 about the causal effect.

118 We formulated z'_Y at different types of IVs to follow distinct distributions.

119 1. Valid IVs: z'_Y at valid IVs asymptotically follows a standard normal distribution, i.e.,

120
$$z'_{Y,\text{valid}} \sim N(0, 1).$$

121 2. Uncorrelated pleiotropic IVs: At uncorrelated pleiotropic IVs, z'_Y follows a normal
122 distribution with a fixed mean parameter μ_1 and an enlarged variance, i.e.,

$$z'_{Y,\text{unc}} \sim N(\mu_1, 1 + \sigma_{eu}^2)$$

123 , where μ_1 and σ_{eu}^2 represent the mean and variance of the uncorrelated pleiotropic effects,
124 respectively.

125 3. Correlated pleiotropic IVs: z'_Y at correlated pleiotropic IVs follows another normal
126 distribution. This distribution is characterized by a mean parameter related to z_X and an
127 enlarged variance, i.e.,

$$z'_{Y,\text{cor}} \sim N(\mu_2 + \mu_a z_X, 1 + z_X^2 \sigma_a^2 + \sigma_{ec}^2)$$

128 , where μ_a and σ_a^2 represent the mean and variance of the pleiotropic correlation,
129 respectively. μ_2 and σ_{ec}^2 represent the mean and variance of the residual pleiotropic effects
130 after adjusting for the pleiotropic correlation.

131 These formulations allow us to account for the different distributions of residual
132 z-scores at various types of IVs, thereby capturing the distinct effects of horizontal
133 pleiotropy on the outcome.

134 Given the presence of multiple independent IVs, we employed the maximum likelihood
135 approach to estimate the parameters from the data. We assumed that the proportions of valid
136 IVs, uncorrelated pleiotropic IVs, and correlated pleiotropic IVs are $(1-\tau)$, $\tau(1-\rho)$, and $\tau\rho$,
137 respectively. Here, τ and ρ , both following within the range $[0,1]$, represent the proportion
138 of total pleiotropic IVs and the relative proportion of correlated pleiotropic IVs, respectively.
139 Our model contains nine parameters in total: $\theta = (r, \mu_1, \mu_2, \mu_a, \sigma_{eu}^2, \sigma_{ec}^2, \sigma_a^2, \tau, \rho)$. We
140 constructed a likelihood function of θ as follows

141
$$L(\theta; \mathbf{z}_X, \mathbf{z}_Y, \mathbf{N}_X, \mathbf{N}_Y) = \prod_{m=1}^M \{(1-\tau)P_{\text{valid}}(z'_{Ym}) + \tau(1-\rho)P_{\text{unc}}(z'_{Ym} | \mu_1, \sigma_{eu}^2) + \tau\rho P_{\text{cor}}(z'_{Ym} | \mu_a, \mu_2, \sigma_a^2, \sigma_{ec}^2)\}.$$

142 Maximizing L with respect to θ provides the maximum likelihood estimate of θ .
143 From this estimate, we can derive both the estimated causal effect, denoted as \hat{r} , and the
144 distribution of pleiotropic effects.

145 To assess the statistical significance of the estimates, we employed the likelihood ratio
146 test (LRT) approach. Specifically, we examined the significance of \hat{r} using a
147 one-degree-of-freedom (df) chi-squared test. This test compares the maximized likelihood
148 value with that obtained for a reduced likelihood function under the setting $r=0$. Additionally,
149 we evaluated the existence of pleiotropic IVs using an 8-df chi-squared test. This test
150 compares the maximized likelihood value with that obtained for another reduced likelihood
151 function under the setting $\tau=0$, in which r is the only model parameter.

152 **The distribution of z'_Y**

153 The distribution of z'_Y is central to our proposed method, Mendelian Randomization
154 analysis using Z-scores (MRZ), as it forms the basis for distinguishing between valid and
155 pleiotropic IVs. Among the two parameters shaping the distribution of z'_Y , variance plays a

156 crucial role in distinguishing between these categories. Through simulations, we investigated
157 the distribution of z'_Y and evaluated the impact of three key factors on its variance: the
158 sample size of the outcome (N_Y), the variance (σ_h^2) of the pleiotropic effect h_Y^2 , and the
159 frequency of positive pleiotropic IVs (f_p). Here, h_Y^2 was defined as the IV-attributable
160 portion of outcome variance, that is, IV-specific outcome heritability. As expected, z'_Y at
161 valid IVs consistently conforms to a standard normal distribution (**Figure 2**). Conversely, at
162 pleiotropic IVs, the variance of z'_Y exceeds one and escalates with increasing N_Y and/or σ_h^2 .
163 Specifically, when all pleiotropic IVs align in the same direction as the IV-exposure effects
164 ($f_p=1$), the variance of z'_Y aligns well with theoretical expectations, which is $\text{var}(\sqrt{N_Y \square_Y^2})$.
165 This variance amplifies when pleiotropic IVs consist of a mixture of positive and negative
166 effects, reaching its maximum when the positive and negative pleiotropic IVs are evenly
167 balanced ($f_p=0.5$).

168 Our simulations also revealed a striking resemblance between the distributions of z'_Y
169 and z_Y . This similarity arises from the positive nature of all z_X by definition, leading to a
170 consistent shift of z_Y towards z'_Y in the same direction across all IVs. Another fact
171 reinforcing this similarity is the typically modest magnitude of the shift Δ , attributed to the
172 small values of r in most real applications (e.g., <0.2). Consequently, we approximated the
173 variance of z'_Y by studying z_Y as if no causal effect were present. By assuming an
174 exponential distribution for pleiotropic effects, we estimated the distribution's sole
175 parameter [40]. Subsequently, we estimated the variance of z'_Y through Monto-Carlo
176 sampling of $\sqrt{N_Y h_Y^2}$. While this estimate assumes all pleiotropic effects align in the same
177 direction and may thus underestimate the true variance, it provides a practical lower

178 boundary from which the optimization of the likelihood function starts to work.

179 **Detecting pleiotropic effects**

180 When all IVs are valid, MRZ does not detect any pleiotropy in both null and causal
181 simulations ($P < 0.05$). Notably, it is more conservative than MRPRESSO [19] and
182 MREGGER [22], both of which identify pleiotropy and horizontal pleiotropy in
183 approximately 5% of iterations.

184 In scenarios where pleiotropic IVs are present, both MRZ and MRPRESSO
185 demonstrate remarkable efficacy, presenting 100% power in detecting pleiotropy even when
186 the proportion of pleiotropic IVs is as low as 10% (**Figure 3A**). Conversely, MREGGER
187 exhibits significantly lower power in discerning the directionality of pleiotropic effects.
188 Even at the highest proportion (60%), MR-EGGER's power rate is only 55.5%.

189 The proportion of pleiotropic IVs estimated by MRZ exhibits a high correlation with
190 the actual proportion, irrespective of the presence of a causal effect or the correlation status
191 of pleiotropic effects (**Figure 3B**). However, a slight overestimate of the mean proportion by
192 a relative proportion of approximately 10% is observed across all scenarios.

193 In instances where correlated pleiotropic IVs are present, MRZ's ability to accurately
194 estimate their proportion is unsatisfactory (**Figure 3C**). This suggests that uncorrelated and
195 correlated pleiotropic IVs are indistinguishable by MRZ. Nevertheless, the per-IV mean
196 correlated pleiotropic effect, defined as $\tau\rho\mu_a$, exhibits a perfect linear relationship with the
197 proportion of correlated pleiotropic IVs (**Figure 3D**). The slope of this linear trend remains
198 consistent between null and causal simulations, indicating minimal influence of the causal
199 effect on the trend. Furthermore, the slope increases with stronger correlated pleiotropic

200 effects and diminishes when no correlated pleiotropic IVs are included. Therefore, MRZ
201 demonstrates the capability to capture correlated pleiotropic effects by jointly modeling the
202 proportion of correlated pleiotropic IVs and the magnitudes of their effects.

203 **Causal effect: type-I error rate**

204 Through a series of null simulations, we evaluated the type-I error rate of MRZ in
205 testing causal effect. For comparative purposes, we incorporated 14 existing two-sample MR
206 methods into our analysis. These include MREGGER [22], IVW [23], weighted-median
207 (W-median) [21], weighted-mode (W-mode) [20], MRPRESSO [19], contamination mixture
208 (CMix) [16], MRMix [18], MRAID [11], MRcML [12], GRAPPLE [13], MRLASSO [17],
209 MRRAPS [14], MRROBUST [17], and CAUSE [15]. It's worth noting that there are other
210 promising methods not included in our analysis, some of which are extensively discussed
211 elsewhere [9].

212 In the absence of pleiotropic effects, MRZ, along with other methods, effectively
213 maintains type-I error rates close to the desired level of 5% (**Table 1**). However, W-mode
214 (0.2%) and CAUSE (0.1%) demonstrate conservativeness, exhibiting lower type-I error
215 rates.

216 In scenarios where pleiotropic effects are present, MRZ consistently maintains the
217 correct type-I error rate across various proportions of pleiotropic IVs, irrespective of
218 whether the pleiotropic effects are uncorrelated or correlated (**Table 2**). This robust
219 performance also holds true under balanced pleiotropic effects (**Supplemental Table 1**).
220 Among alternative methods, W-mode and CAUSE tend to be overly conservative, resulting
221 in significantly reduced type-I error rates in all scenarios (**Table 2**). MREGGER shows

222 validity only when pleiotropic effects are uncorrelated but exhibits an inflated type-I error
223 rate of up to 28.1% when the pleiotropic effects are correlated. MRMix generally performs
224 well under low to modest proportions of pleiotropic IVs but shows an inflated error rate
225 reaching up to 21.6% under higher proportions. All the other alternative methods have
226 inflated type-I error rates that increase with increased proportion of pleiotropic IVs, whereas
227 the inflation is more severe under correlated pleiotropy than under uncorrelated pleiotropy.
228 The type-I error rates for certain methods can reach nearly 100% in some extreme scenarios,
229 rendering them invalid at all under such conditions. Even when the pleiotropic effects are
230 balanced, the inflation of type-I error rates is still observed for most alternative methods,
231 especially in correlated pleiotropic scenarios (**Supplemental Table 1**).

232 Further simulation studies involving a smaller set of 100 IVs (**Supplemental Table 2**)
233 or a larger set of 500 IVs (**Supplemental Table 3**) reaffirm the validity of MRZ. Among
234 alternative methods, W-mode and CAUSE exhibit inflated type-I error rates under high
235 proportions of pleiotropic IVs when the number of IVs is 100 and 500, respectively,
236 rendering them invalid (**Supplemental Tables 2-3**). Therefore, our simulations reveal
237 MRZ's efficacy in rectifying horizontal pleiotropy across diverse confounding scenarios,
238 where existing methods often lose validity.

239 Notably, MRZ demonstrates strong robustness against sample overlap due to its
240 effective control of horizontal pleiotropy. It maintains a valid type-I error rate even when
241 exposure and outcome samples completely overlap (**Supplemental Table 4**), making it
242 suitable for scenarios involving a single biobank-scale dataset such as the UKB cohort.

243 **Causal effect: power and effect size**

244 We conducted a series of causal simulations to examine the power and effect size of
245 various methods. In scenarios without pleiotropic effects, nearly all alternative liberal
246 methods—those prone to type-I error under pleiotropic scenarios—demonstrate remarkably
247 high power rates almost reaching 100% (**Table 1**). MRZ notably achieves a power rate of
248 99.9%, positioning it among the most powerful methods. Conversely, W-mode exhibits the
249 lowest power rate (10.4%), followed by MRMix (25.9%) and CAUSE (80.0%). Regarding
250 effect size estimation, most methods, including MRZ, estimate mean effect sizes close to the
251 true value of 0.050. MRZ displays one of the lowest mean errors (MEs, 0.008) among all
252 methods. In contrast, W-mode (0.033) and MRMix (0.025) exhibit larger variations.

253 In the presence of horizontal pleiotropy, MRZ exhibits a decline in power as the
254 proportion of pleiotropic IVs increases, as expected. This decline is similar in both positive
255 and negative causal effect settings (**Supplemental Table 5**), indicating minimal impact of
256 pleiotropic effects on MRZ's power across diverse scenarios. Even with the highest
257 proportion of 60% pleiotropic IVs, MRZ's power rate maintains between 40%-58%.

258 Alternative methods demonstrate scenario-dependent performance, lacking a universal
259 trend across all settings. The two overly conservative methods CAUSE and W-mode, along
260 with MREGGER, MRMix and MRAID, generally exhibit declining power with increased
261 proportion of pleiotropic IVs (**Supplemental Table 5**). For other alternative methods, two
262 distinct trends are observed depending on the relative directions of the causal effect and the
263 pleiotropic effects. When they align, these methods maintain high power rates at nearly 100%
264 at all proportions of pleiotropic IVs. Conversely, when they oppose, these methods
265 experience rapid decline in power rates with increased proportion of pleiotropic IVs

266 **(Supplemental Table 5)**. These conflicting trends highlight potential confounding effects of
267 uncorrected pleiotropy on power estimation.

268 To ensure a fair comparison of power rates among methods despite varying type-I error
269 rates, we corrected each method's raw power rate by its type-I error rate at the corresponding
270 null setting, assuming a correct type-I error rate of 5%. Like MRZ, all alternative methods
271 have a decrease in their corrected power rates when the proportion of pleiotropic IVs
272 increases **(Figure 4)**. Among the methods, MRZ generally maintains the highest corrected
273 power rate across various proportions of pleiotropic IVs. This improvement is particularly
274 notable when the causal effect opposes the pleiotropic effects, in which cases uncorrected
275 pleiotropic effects counteract or even reverse the true causal effect, resulting in a severe loss
276 of power for alternative methods.

277 Uncorrected pleiotropic effects not only affect the power to detect the causal effect but
278 also influence estimated effect size. MRZ's estimated effect sizes align with the true value
279 (0.05 or -0.05) across all scenarios **(Figure 5)**, regardless of the proportion of pleiotropic IVs
280 or the direction of the causal effect. Conversely, for all alternative methods, including
281 W-mode and CAUSE, distinct trends are observed based on the relative directions of the
282 causal effect to pleiotropic effects. When the directions align, mean effect sizes of all
283 alternative methods tend to increase with the proportion of pleiotropic IVs, whereas they
284 decrease when the directions oppose. At the highest proportion of 60% pleiotropic IVs, the
285 decrease is so severe that the estimated effect sizes from all alternative methods are opposite
286 to the true size.

287 Additional simulation studies with 100 and 500 IVs **(Supplemental Figure 1)** reveal an

288 increased trend of MRZ's power rate with an increasing number of IVs, underscoring the
289 critical importance of including a substantial number of IVs for robust and powerful causal
290 inference.

291 When modeling no pleiotropic effects, the proposed test statistic T_1 closely
292 approximates the causal effect size estimated by the IVW test across all simulated scenarios
293 (**Supplemental Figure 2**). This suggests that the IVW test provides a reasonable anchor for
294 MRZ to adjust its estimated effect size when analyzing un-standardized summary statistics,
295 such as case-control data.

296 **Running time**

297 The computation process of MRZ primarily focuses on optimizing the likelihood
298 function twice: once for the alternative hypothesis and once for the null hypothesis. Despite
299 involving a high dimension of nine parameters, the derivative-free optimization algorithm
300 *nmb* that we employed offers an efficient solution. MRZ completes the optimization within
301 seconds even on datasets containing 500 IVs. However, it's important to acknowledge that
302 there is no assurance that the optimization algorithm will converge to its global maximum
303 under such a high-dimensional parameter space. Therefore, it's recommended to conduct
304 repeated optimizations with varying initial parameter settings to enhance the likelihood of
305 obtaining a robust solution. In this study, a total of 20 repeats were performed to ensure the
306 reliability of the results.

307 **Real data analysis**

308 As an application, we conducted a bidirectional MR study examining the relationship
309 between ALM and four circulating lipid traits (high-density lipoprotein cholesterol (HDL-C),

310 low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglycerides (TG)).

311 We utilized two data sources: the UKB internal cohort and the summary statistics released
312 by GLGC.

313 In the UKB-internal analysis, we randomly divided the entire UKB cohort into two
314 independent sub-samples (UKB_S1 and UKB_S2). For each exposure-outcome pair (e.g.,
315 ALM-TC), one sub-sample served as the exposure sample while the other served as the
316 outcome sample. This process was repeated twice by reversing the roles of the two
317 sub-samples so that two independent sets of summary statistics were generated [41]. In the
318 UKB-GLGC joint analysis, we used the entire UKB cohort to generate GWAS summary
319 statistics for ALM, while GLGC data (excluding UKB participants) provided summary
320 statistics for the lipid traits. Consequently, we generated three datasets that are mutually
321 independent in exposure and/or outcome, allowing for cross-validation of results.

322 To assess robustness against sample overlap, we conducted an MR analysis using both
323 exposure and outcome summary statistics derived from the entire UKB cohort, resulting in
324 complete sample overlap.

325 Observational analyses reveal significant correlations between raw ALM values and all
326 lipid traits in the UKB cohort, and these correlations persist after adjusting for age and sex in
327 both ALM and lipid traits (**Supplemental Table 6**). In the MR settings, the number of
328 eligible IVs ranges from 85 to 719 across all exposure-outcome pairs (**Supplemental Tables**
329 **7-8**). Strong IV-exposure associations are observed, with R^2 values ranging from 0.05 to 0.10
330 and F -statistics ranging from 52.1 to 188.8.

331 At a significance level of 6.25×10^{-3} ($0.05/(2 \times 4)$), forward MRZ analysis identified a
332 negative association between ALM and both TC and LDL-C (**Table 3**). This association is
333 statistically significant in all three datasets for both traits, strengthening the evidence of
334 causality. The estimated effect sizes are consistent across datasets for both TC (-0.079,
335 -0.083 and -0.074) and LDL-C (-0.054, -0.063 and -0.037). Notably, the proportion of
336 pleiotropic IVs was estimated to be modest to high for both traits, being around 30% and 40%
337 in the UKB-internal datasets (261-268 IVs).

338 Forward MR analyses using MRZ did not detect significant associations between ALM
339 and either HDL-C or TG in any of the datasets, suggesting no causal effects on both traits.
340 Further reverse MR analyses did not identify significant associations for any lipid traits with
341 ALM, indicating no reverse causal effect. Analysis on the completely overlapped whole
342 UKB cohort yielded similar results (**Supplemental Table 9**), confirming MRZ's robustness
343 against sample overlap.

344 We compared the MRZ results with those from alternative methods. In the forward MR
345 analyses, all alternative methods identified the same negative causal effect of ALM on TC in
346 one or more datasets (**Supplemental Figure 3**). However, in the reverse MR analyses, all
347 alternative methods revealed a same negative causal effect of TC on ALM in at least one
348 dataset (**Supplemental Figure 3**). The results of mutual causality at the same direction are
349 observed from alternative methods on the other three lipid traits too (**Supplemental Figures**
350 **4-6**). Observing mutually reinforcing causal effects at the same direction suggests a high
351 likelihood of pleiotropy, making it difficult to definitively determine the true causal
352 relationship. Therefore, leaving aside the true causal relationships, none of the alternative

353 methods can produce results that are free of pleiotropic effects and that are self-validated
354 across all datasets.

355 **Experimental validation**

356 Given the unidirectional causal link identified by MRZ versus the disputed
357 bidirectional link suggested by alternative methods, there are conflicting views on the causal
358 effect of lipid traits on ALM. To address this controversy empirically, we conducted an *in*
359 *vivo* randomized controlled experiment using a mouse model. The experiments involved
360 intervention with TC and compared to normal controls. The results reveal a significant
361 increase in circulating TC levels in mice fed TC for a period of 8 weeks ($N=12$) compared to
362 normal controls ($N=12$, Wilcoxon rank test $P=3.59\times 10^{-5}$, **Figure 6**), indicating successful
363 implementation of the TC intervention. Additionally, significant changes are observed in
364 HDL-C ($P=1.24\times 10^{-14}$), LDL-C ($P=5.98\times 10^{-9}$), and TG ($P=5.98\times 10^{-5}$) levels.

365 As the outcome, we observed a significant increase in total body mass ($P=1.64\times 10^{-3}$)
366 and fat body mass ($P=1.03\times 10^{-4}$) in the TC intervention group. However, there is no
367 significant difference in lean body mass ($P=0.80$), suggesting no causal effect of lipid traits
368 on ALM. These findings are consistent with the results obtained from MRZ analyses, but
369 differ from the conclusions drawn by most alternative methods. This highlights MRZ's
370 resilience against horizontal pleiotropic effects, to which existing methods are more
371 susceptible.

372

Discussion

373 Under the prevailing polygenic genetic architecture of complex traits, pleiotropy is
374 anticipated to be a common occurrence [42]. While theoretical assertions suggest that
375 perfectly balanced pleiotropic effects could cancel out bias [22], achieving such equilibrium
376 is impractical. Current MR practices often employ sensitivity analyses like the MREGGER
377 intercept test to evaluate pleiotropy balance [22]. However, our simulation studies revealed
378 that the MREGGER intercept test lacks sufficient power to detect even substantial
379 pleiotropic imbalances. Thus, relying solely on these methods cannot ensure that empirical
380 MR analyses are conducted under balanced pleiotropic conditions. Even under balanced
381 pleiotropy, our simulation studies demonstrated that the type-I error rate of certain methods
382 may inflate as the proportion of pleiotropic IVs increases. The presence of correlated
383 pleiotropic effects exacerbates this issue. Therefore, robust methods to address horizontal
384 pleiotropy are crucial to ensure the validity of MR analyses.

385 Our proposed method, MRZ, categorizes IVs into three distinct groups reflecting
386 potential pathways from IVs to the outcome, as depicted in the classical MR rationale
387 diagram. By assuming a general normality distribution for underlying pleiotropic effects, we
388 derived a precise distribution for IV-outcome z-scores specific to each category. In simulated
389 scenarios encompassing diverse pleiotropic settings, MRZ demonstrates enhanced control of
390 type-I error rate as well as more precise and powerful causal effect estimation than existing
391 methods. Notably, the normality assumption assumed by MRZ was not met in our
392 simulations. However, we did not observe inflated type-I error rates or imprecise effect
393 estimates, demonstrating the robustness of MRZ against data distribution.

394 Multiple sophisticated models have been proposed to address horizontal pleiotropy in
395 MR analyses, with some examples provided in this study. While these methods demonstrate
396 excellent performance under specific conditions, our simulation studies reveal limitations
397 when the number of IVs reaches the hundreds. In such scenarios, certain alternative methods
398 struggle to effectively correct for pleiotropic effects. This challenge arises because
399 pleiotropic effects are often systematic, meaning they are not simply averaged out with an
400 increasing number of IVs. In fact, the presence of systematic pleiotropy can worsen as the
401 number of IVs grows.

402 Among alternative methods, MRMix shares a similar strategy of categorizing IVs based
403 on their potential causal effects [18]. However, MRMix utilizes four categories reflecting all
404 combinations of the presence or absence of direct effects between IVs and both the exposure
405 and the outcome. This classification allows MRMix to include IVs with no association to the
406 exposure. In contrast, MRZ assumes all IVs to be associated with the exposure, aligning
407 with the standard practice of screening and filtering IVs in empirical MR analyses to ensure
408 this condition.

409 Another key distinction between MRZ and MRMix lies in the data modeling strategy.
410 MRMix assumes both IV-exposure and IV-outcome effects are random variables following a
411 bivariate normal distribution. Conversely, MRZ treats the IV-exposure effect as a fixed value
412 and models only the IV-outcome effect as a random variable with a distribution conditional
413 on the former. This approach in MRZ eliminates the requirement for a normality assumption
414 on the IV-exposure effect, making it more robust to non-normality, a frequent characteristic
415 in non-infinitesimal genetic models.

416 Another comparable method, CMix, employs distinct probability functions to model
417 valid and pleiotropic IVs as well. Key disparities between MRZ and CMix include the
418 following: 1) MRZ categorizes pleiotropic IVs into uncorrelated and correlated groups,
419 offering a more detailed classification compared to CMix, which treats all pleiotropic IVs
420 collectively; 2) Both methods assume a normal distribution for effect sizes of pleiotropic IVs.
421 However, MRZ allows the mean parameter of this distribution to vary freely, while CMix
422 constrains it to zero but allows for an expanded variance; 3) MRZ integrates uncertainty
423 regarding IV validity into its likelihood function without explicitly designating each IV as
424 valid or pleiotropic. Conversely, CMix explicitly assigns a label to each IV based on its
425 estimated probability of being valid or pleiotropic under each parameter setting. We argue
426 that incorporating IV uncertainty may provide valuable insights into the distribution of
427 pleiotropic IVs. Our simulation studies demonstrate that MRZ can effectively estimate the
428 proportion of pleiotropic IVs, thereby supporting its efficacy.

429 Skeletal muscle and circulating lipids play a critical role in regulating energy balance
430 [43-45]. They are intricately linked and share common genetic background [46, 47]. Our real
431 data analysis revealed a high degree of pleiotropy between ALM and all the lipid traits we
432 examined. This pleiotropy poses a significant challenge for most existing MR methods.
433 These methods tend to have inflated type-I error rates when the proportion of pleiotropic IVs
434 is modest to high. As evidence, all alternative methods discovered a causal effect of TC on
435 ALM in at least one dataset. However, this finding contradicted the results of controlled
436 experiments where TC levels were directly manipulated. In contrast, MRZ yielded a
437 different result that aligned with the experiment results. This highlights the importance of

438 robust methods for accurate causal inference in MR studies, especially when pleiotropy is a
439 major concern.

440 The observed causal effect of ALM on TC and LDL-C in our real data analysis is
441 supported by nearly all alternative methods. Several plausible biological mechanisms could
442 underlie this causality: 1) Metabolic rate and energy balance: Lean mass contributes
443 significantly to basal metabolic rate [48, 49], which in turn can influence lipid metabolism
444 and cholesterol levels. 2) Insulin sensitivity: Muscle tissue plays a crucial role in glucose
445 metabolism and insulin sensitivity [50]. Higher lean mass is often associated with improved
446 insulin sensitivity and glucose uptake [50], which in turn lead to changes in TC and LDL-C
447 levels [51]; 3) Anti-inflammatory effects of muscle: Muscle secretes beneficial hormones
448 such as interleukin-6 (IL-6) and irisin [52, 53], which have anti-inflammatory properties.
449 These hormones can influence lipid metabolism and cholesterol levels [54, 55].

450 It should be notable that ALM is usually altered by other modifiable factors such as
451 exercise and diet. In this case, they are in the same causal pathway, and it is unclear whether
452 the changes in circulating TC and LDL-C are directly caused by changes in ALM or if ALM
453 acts as a mediator of some modifiable factor. Further investigation is warranted to elucidate
454 the biological mechanism underlying this causal relationship.

455 Certain limitations exist in the proposed method. Firstly, it does not account for certain
456 biases common in MR analyses, such as weak instrument bias [56] and winner's curse bias
457 [57]. These biases can potentially be mitigated by implementing stringent IV filtering, such
458 as applying a more rigorous significance threshold [57]. Secondly, optimizing a
459 high-dimensional likelihood function poses challenges in converging to its global solution.

460 To enhance the likelihood of reaching the global maximum, it is advisable to perform
461 multiple optimizations with varying initial parameters. However, this approach increases
462 computational burden and does not guarantee attainment of the global maximum. Thirdly,
463 the proposed method requires both exposure and outcome sample sizes as input, unlike other
464 methods that do not have this requirement. This necessity arises because z-scores are
465 meaningful only within the context of a specific sample size. If exposure and outcome
466 sample sizes are uniform so that their ratios are constant across all IVs, then the detailed
467 sample sizes are indeed unnecessary because the estimated effect size remains unchanged
468 after calibrating to the effect size estimated by the IVW test. However, if sample sizes vary
469 across IVs, then providing this information is essential for unbiased estimation by the
470 proposed method. Furthermore, in scenarios involving case-control studies with imbalanced
471 case-to-control ratios, employing an effective sample size rather than a raw sample size is
472 preferable for accurate estimation [58].

473 In summary, we have proposed a novel two-sample MR method that demonstrates
474 robustness against horizontal pleiotropic effects, while also offering accuracy and power
475 across a wide range of scenarios. By applying this method to investigate the relationship
476 between ALM and lipid traits, we identified a negative causal effect of ALM on TC and
477 LDL-C. Our proposed method serves as a valuable alternative to existing MR methods,
478 particularly in the analysis of large-scale biobank datasets with numerous IVs. With its
479 ability to provide reliable and precise causal inference, our method contributes to advancing
480 the field of MR analysis and enhances our understanding of complex biological
481 relationships.

482

Online methods

483 Basic model

484 We assumed a continuous exposure trait X , a continuous outcome trait Y , and a
485 bi-allelic SNP G taking values between 0, 1, and 2. For ease of presentation, we assumed X
486 and Y are standardized so that their variances are one. Assumed that G is associated with X
487 and serves as its IV and that the associations of G with both X and Y were tested under an
488 additive mode of inheritance.

489 The basic phenotype model for MR analysis was formulated as following

$$490 \quad X = \beta_1 G + \varepsilon_X,$$

$$Y = rX + \varepsilon_Y = (r\beta_1)G + \varepsilon'_Y$$

491 , where β_1 measures the effect of G on X , r measures the causal effect of X on Y , and ε_X
492 and ε_Y (ε'_Y) are independently and normally distributed random errors. Here, we used the
493 term r for a causal effect of X on Y because it is equivalent to the correlation coefficient for
494 two standardized phenotypes.

495 In the above model, the parameter r is the focus of MR analysis. In a typical
496 two-sample MR analysis, regression coefficients of both X and Y on G are available from
497 GWAS analyses, denoted by $\hat{\beta}_1$ and $\hat{\beta}_G^Y$. Then an unbiased estimator of r would be [23]

$$498 \quad \hat{r} = \frac{\hat{\beta}_G^Y}{\hat{\beta}_1}.$$

499 Below, we modeled the estimation problem using the genetic association z-score, which
500 is defined as the regression coefficient divided by its standard error. Specifically,

$$501 \quad z_X = \frac{\hat{\beta}_1}{\hat{\sigma}_1}, \text{ and } z_Y = \frac{\hat{\beta}_G^Y}{\hat{\sigma}_G^Y}$$

502 , where $\hat{\sigma}_1$ and $\hat{\sigma}_G^Y$ are standard errors of $\hat{\beta}_1$ and $\hat{\beta}_G^Y$.

503 The squared z -score statistic, termed s_X or s_Y , is commonly used to test the genetic
 504 association between G and X or Y . When there is no association, the s statistic asymptotically
 505 follows a 1-df central chi-squared distribution. Accordingly, the z -score asymptotically
 506 follows a standard normal distribution. In contrast, when genetic association exists, the s
 507 statistic asymptotically follows a 1-df non-central chi-squared distribution characterized by a
 508 non-central parameter (NCP) λ , and the z -score asymptotically follows a normal distribution
 509 with variance one but with a non-zero mean parameter μ where $\mu^2 = \lambda$, i.e.,

$$510 \quad z \xrightarrow{d} N(\mu, 1),$$

$$511 \quad s = z^2 \xrightarrow{d} \chi_1^2(\lambda).$$

512 In our previous study, we proved that the NCP parameter λ is a function of sample
 513 size N and SNP effect size h^2 [40]. Specifically,

$$\lambda = N \times \ln\left(\frac{1}{1-h^2}\right) \approx Nh^2, \text{ for } h^2 \ll 1$$

514 , where $\ln(\cdot)$ represents natural logarithm transformation, and h^2 is the portion of phenotypic
 515 variance explained by the SNP, e.g., the SNP-specific heritability. Specifically, we had

$$516 \quad h_X^2 = \frac{\text{var}(\beta_{1G})}{\text{var}(X)}, \text{ and } h_Y^2 = \frac{\text{var}(r\beta_{1G})}{\text{var}(Y)} = h_X^2 r^2$$

517 , so that the mean parameters for X and Y have the following forms

$$518 \quad \mu_X = \sqrt{\lambda_X} = \sqrt{N_X h_X^2}$$

$$\text{, and } \mu_Y = \sqrt{N_Y h_Y^2} = \sqrt{\frac{N_Y}{N_X}} \times r\mu_X$$

519 Clearly, the mean parameter μ_Y is completely determined by μ_X and their causal effect r .

520 In the above formula, the parameter μ_X is unknown and could be estimated from the
 521 GWAS summary statistics with the following formula

$$\hat{\mu}_X = \sqrt{\frac{N_X \hat{\beta}_1^2 \times 2f(1-f)}{\text{var}(X)}}$$

522 , where f is minor allele frequency (MAF) of the IV. However, in practical released GWAS
523 summary statistics X may not be standardized so that its variance $\text{var}(X)$ is unknown. In this
524 case, recall that

$$525 \quad p(z_X | \mu_X) = \frac{1}{\sqrt{2\pi}} e^{-\frac{(z_X - \mu_X)^2}{2}}.$$

526 Therefore, we replaced μ_X by its maximum likelihood estimation, which is z_X , and re-wrote
527 the form of μ_Y

$$528 \quad \mu_Y = \sqrt{\frac{N_Y}{N_X}} \times r z_X = \Delta \quad (1)$$

529 Given Δ , the probability of observing z_Y is simply the density of a normal distribution
530 $N(\Delta, 1)$. Equivalently, if we let $z'_Y = z_Y - \Delta$, then z'_Y follows a standard normal
531 distribution $N(0, 1)$

$$532 \quad z'_Y = z_Y - \Delta \xrightarrow{d} N(0,1).$$

533 **Estimating r using z-scores**

534 When multiple independent IVs are available, we built the estimation model within the
535 maximum likelihood framework. Assumed that there are a total of M independent IVs. Let
536 $\mathbf{z}_X = (z_{X1}, z_{X2}, \dots, z_{XM})'$ and $\mathbf{z}_Y = (z_{Y1}, z_{Y2}, \dots, z_{YM})'$ be corresponding z-score vectors.

537 We constructed the likelihood function of r as

$$538 \quad L(r; \mathbf{z}_X, \mathbf{z}_Y, N_X, N_Y) = \prod_{m=1}^M p(z'_{Ym}).$$

539 Maximizing the likelihood function $L(r)$ yielded the maximum likelihood estimate of r ,
540 denoted by \hat{r} , and the maximum likelihood, denoted by $L(\hat{r})$.

541 The significance of \hat{r} was evaluated using the LRT approach. Specifically, by
542 restricting $r=0$, we obtained the null likelihood L_0 . We then constructed the likelihood ratio

543 test statistic as follows

$$544 \quad T_1 = -2(\log(L_0) - \log(L(\hat{r}))). \quad (2)$$

545 Under the null hypothesis of $r=0$, T_1 approximately follows a 1-df central chi-squared
546 distribution, which is used to judge the significance of \hat{r} .

547 **Modeling uncorrelated and correlated horizontal pleiotropy effects**

548 We defined an IV to be valid if it has no horizontal pleiotropic effect. For a pleiotropic
549 IV, the estimator \hat{r} is not necessarily an unbiased estimator of r anymore. To see this, we
550 re-wrote the phenotype model for Y as

$$\begin{aligned} Y &= rX + \beta_2 G + \varepsilon_Y \\ &= (\beta_1 r + \beta_2)G + \varepsilon'_Y \end{aligned}$$

551 , where β_2 measures the pleiotropic effect of G on Y that is not mediated by X . In this
552 model, \hat{r} is an unbiased estimator of the following parameter instead

$$553 \quad E(\hat{r}) = E\left(\frac{\hat{\beta}_G^Y}{\hat{\beta}_1}\right) = r + \frac{\beta_2}{\beta_1}.$$

554 Depending on the direction of β_2 , \hat{r} could overestimate or underestimate the true effect r .

555 In the presence of pleiotropy, the association of G with Y is a mixture of the X -mediated
556 causal effect and the pleiotropic effect. Accordingly, the mean parameter μ_Y is a mixture of
557 two components (**Supplemental Notes**)

$$\mu_Y = \Delta + \mu_P$$

558 so that

$$559 \quad z'_Y = (z_Y - \Delta) \xrightarrow{d} N(\mu_P, 1) \quad (3)$$

560 , where $\mu_P^2 = N_Y h_P^2$ is a parameter defined by pleiotropy driven heritability

$$561 \quad h_P^2 = \frac{\text{var}(\beta_2 G)}{\text{var}(Y)}.$$

562 In the above formula, the mean parameter μ_Y is composed of two components: the
563 first one is the causal effect, and the second one is the pleiotropic effect. The causal effect is
564 fixed for not only valid IVs but also pleiotropic IVs. In contrast, the pleiotropic effect exists
565 at pleiotropic IVs only and may vary depending on the strength of the IV-outcome effect,
566 and was therefore modeled as a random effect. After removing the causal effect, the residual
567 outcome z-score contains information about the pleiotropic effect only. Depending on
568 whether it is correlated to z_X or not, the pleiotropic effect is further classified into two types.
569 In the first type, the pleiotropic effect is directly on the outcome, so it is uncorrelated to z_X .
570 In this case, μ_P was modeled as a z_X -independent normally distributed effect

$$571 \quad \mu_{P_{\text{unc}}} = \mu_1 + \varepsilon_1, \quad \varepsilon_1 \sim N(0, \sigma_{\varepsilon u}^2).$$

572 In the second type, the pleiotropic effect is influenced by some unmeasured confounder
573 that is correlated to both the exposure and the outcome. μ_P in this type is correlated to z_X
574 and the INSIDE assumption is violated [39]. Accordingly, it was modeled as a z_X -related
575 normally distributed effect

$$\mu_{P_{\text{cor},m}} = \mu_2 + a_m z_{Xm} + \varepsilon_2, \quad \varepsilon_2 \sim N(0, \sigma_{\varepsilon c}^2)$$

576 , where a_m measures the correlation between $\mu_{P_{\text{cor},m}}$ and z_{Xm} at the m th IV. We added the
577 subscript m in $\mu_{P_{\text{cor}}}$ to emphasize that a_m is IV-specific whose magnitude depends on the
578 magnitude of the pleiotropy effect at the m th IV. To account for the variation of a_m , it was
579 further modeled as a normally distributed random effect

$$580 \quad a_m \sim N(\mu_a, \sigma_a^2),$$

581 where μ_a and σ_a^2 measure mean pleiotropic correlation and its variance, respectively.

582 Until now, we have built a hierarchical model towards the mean parameter of z'_Y

583 distribution. We aimed to obtain its marginal distribution. To integrate out the intermediate
 584 dummy variables, we introduced the following lemma,

585 *Lemma I, If a random variable X follows a normal distribution $X \sim N(\mu, \sigma_1^2)$, and if its mean*
 586 *parameter μ is another random variable following a second normal distribution*
 587 *$\mu \sim N(\mu_1, \sigma_2^2)$, then the marginal distribution of X is again a normal distribution of the form*
 588 *$X \sim N(\mu_1, \sigma_1^2 + \sigma_2^2)$ (Supplemental Notes).*

589 Applying this lemma, we first integrated out a_m to obtain the marginal distribution of $\mu_{P_{cor}}$

$$590 \quad \mu_{P_{cor}} \sim N(\mu_2 + \mu_a z_X, z_X^2 \sigma_a^2 + \sigma_{ec}^2).$$

591 We then in turn integrated out $\mu_{P_{unc}}$ and $\mu_{P_{cor}}$ to obtain the marginal distribution of z'_Y

$$z'_{Y,unc} \sim N(\mu_1, 1 + \sigma_{eu}^2)$$

592 and

$$593 \quad z'_{Y,cor} \sim N(\mu_2 + \mu_a z_X, 1 + z_X^2 \sigma_a^2 + \sigma_{ec}^2).$$

594 Taken together, for the three types of IVs (valid, uncorrelated pleiotropic and correlated
 595 pleiotropic), the residual z-score z'_Y after removing the causal effect r has a type-specific
 596 distribution

$$597 \quad z'_Y \sim \left\{ \begin{array}{l} N(0,1), \text{ valid IV;} \\ N(\mu_1, 1 + \sigma_{eu}^2), \text{ uncorrelated pleiotropic IV;} \\ N(\mu_2 + \mu_a z_X, 1 + z_X^2 \sigma_a^2 + \sigma_{ec}^2), \text{ correlated pleiotropic IV.} \end{array} \right\}. \quad (4)$$

598 One key inference from the above distributions is that z'_Y at different types has distinct
 599 variances. Specifically, z'_Y at valid IVs has an exact variance of one. z'_Y at pleiotropic IVs
 600 has a greater variance. This feature may make the three types of IVs distinguishable.

601 Likelihood function under horizontal pleiotropy

602 We assumed that the proportions of valid IVs, uncorrelated pleiotropic IVs and
 603 correlated pleiotropic IVs are $(1-\tau)$, $\tau(1-\rho)$, and $\tau\rho$, where τ and $\rho \in [0,1]$ measure the

604 proportion of pleiotropic IVs and the relative proportion of correlated pleiotropic IVs,
605 respectively. Our model contains nine parameters in total:

606 $\theta = (r, \mu_1, \mu_2, \mu_a, \sigma_a^2, \sigma_{eu}^2, \sigma_{ec}^2, \tau, \rho)$. We constructed a likelihood function of θ as follows

607
$$L(\theta; \mathbf{z}_x, \mathbf{z}_y, N_x, N_y) = \prod_{m=1}^M \{(1 - \tau)P_{\text{valid}}(z'_m) + \tau(1 - \rho)P_{\text{unc}}(z'_m | \mu_1, \sigma_{eu}^2) + \tau\rho P_{\text{cor}}(z'_m | \mu_a, \mu_2, \sigma_a^2, \sigma_{ec}^2)\} \quad (5)$$

608 , where the probability densities were defined by equation (4).

609 Maximizing L regarding θ yields the maximum likelihood estimate of θ , denoted by
610 $\hat{\theta}$, and the maximum likelihood, denoted by $L(\hat{\theta})$. We maximized L using the function *nmkb*
611 in the R package *dfoptim*, which implements a derivative-free Nelder–Mead algorithm for
612 high-dimensional function.

613 **Test of causal effect**

614 The causal effect is tested against the null hypothesis of $r=0$ by means of the LRT
615 approach. Specifically, by restricting $r=0$ in (5), we constructed the null likelihood function,
616 denoted by L_0 , which contains eight parameters. Maximizing L_0 over its sample space yields
617 the maximum likelihood under the null hypothesis, denoted by $L_0(\hat{\theta}_0)$. The LRT statistic was
618 then constructed as follows

619
$$T_2 = -2(\log(L_0(\hat{\theta}_0)) - \log(L(\hat{\theta}))). \quad (6)$$

620 Under the null hypothesis of $r=0$, T_2 approximately follows a 1-df central chi-squared
621 distribution, which was used to declare the significance of \hat{r} .

622 **Test of pleiotropic effects**

623 The existence of pleiotropic effects was tested against the null hypothesis of $\tau=0$ using
624 the same LRT approach. Under the null hypothesis, the likelihood function contains only one
625 free parameter r . Therefore, we used a 8-df central chi-squared distribution to declare the

626 significance of the estimate $\hat{\tau}$.

627 In implementation, we will first test pleiotropic effects at the significance level $P < 0.05$.

628 If there is evidence of pleiotropic effects, then we will use T_2 to test the causal effect;

629 otherwise, we will use T_1 instead.

630 **Unstandardized phenotypes**

631 Since $\hat{\tau}$ is estimated based on z-scores, its test significance remains unchanged

632 regardless of whether exposure or outcome is standardized. However, its magnitude may

633 differ from the original effect size when unstandardized exposure or outcome is analyzed.

634 The ratio of $\hat{\tau}$ to the original effect size is a constant C that is determined by the unit of

635 exposure and outcome under analysis. In certain scenarios, it is desirable to obtain the

636 original effect size, such as to recover the odds ratio for case-control data types.

637 To recover the original effect size, we estimated C by anchoring our test to a

638 comparable alternative test. As demonstrated in the Results section, our proposed test

639 statistic T_1 , which assumes no pleiotropic effects, yields an effect size approximately equal

640 to the IVW test, which also assumes no pleiotropic effects. Consequently, we conducted both

641 the T_1 test and the IVW test on the same dataset and estimated C by calculating the ratio of

642 their effect sizes.

643 **Simulation studies**

644 We performed a series of simulation studies to evaluate the performance of the

645 proposed method. We simulated one continuous exposure X , one continuous outcome Y and

646 one continuous confounder U . We simulated a set of bi-allelic SNP as IVs for the exposure.

647 We studied a two-sample context so that the exposure and outcome summary statistics were

648 generated from two separate samples. Parameter settings were as follows:

649 1) The number of IVs was set to be $M=200$.

650 2) Both exposure and outcome sample sizes were set to be $N_X=N_Y=200,000$.

651 3) The causal effect of X on Y was set to be $r=0$ (null), 0.05 (positive effect), or -0.05
652 (negative effect). In the latter two cases, X explained $r^2=0.25\%$ of Y 's variance.

653 4) Confounder effect. In the case of confounding effect, the effect of the confounder U was
654 set to explain 20% of phenotypic variance in both X and Y . The effect directions of U on
655 both X and Y were set to be the same.

656 5) Proportion of pleiotropic IVs to the outcome (τ). The proportion of pleiotropic IVs τ
657 varied from 10% to 60% at an increment of 10%. The default direction of the pleiotropic
658 effects was assumed to be positively dominated, in which 70% : 30% of pleiotropic IVs
659 were simulated to have positive : negative pleiotropic effects. In the case of balanced
660 pleiotropic effects, 50% : 50% of pleiotropic IVs were simulated to have positive : negative
661 pleiotropic effects.

662 6) Relative proportion of correlated IVs (ρ). From the pleiotropic IVs simulated in step 5),
663 a fraction of $\rho = 0.5$ IVs were simulated to also have a pleiotropic effect on U . For ease of
664 presentation, the direction of the pleiotropic effects on U was set to be the same as that on Y .

665 7) IV effects on exposure. We assumed a non-infinitesimal genetic architecture for
666 IV-exposure effects. A proportion of 10% of total IVs were simulated to have a large effect
667 each explaining 0.2% of X 's variance. The portion of explained variance for each of the
668 remaining 90% IVs was drawn from an exponential distribution with a mean 1.0×10^{-4} , a
669 level comparable to the majority of GWAS findings. The 200 IVs explained approximately a

670 total of 5.8% of X 's variance.

671 8) IV pleiotropic effects on outcome and confounder. The portion of the variance in both Y
672 and U explained by each pleiotropic IV was drawn from an exponential distribution with a
673 mean 1.0×10^{-4} .

674 Each scenario was simulated with 1,000 iterations. At each simulation iteration, the
675 MAF of each IV was drawn from a uniform distribution $uni(0.05, 0.5)$, and the IV genotypes
676 at both exposure and outcome samples were simulated using PLINK [59] assuming the
677 Hardy-Weinberger equilibrium. After the phenotypes were simulated, PLINK was invoked
678 to test genetic association in both the exposure and the outcome samples.

679 **Comparison with existing methods**

680 We evaluated and compared the performance of the proposed method with 14 existing
681 two-sample MR methods, including IVW [23], MREGGER [22], weighted-median
682 (W-median) [21], weighted-mode (W-mode) [20], MRPRESSO [19], the contamination
683 mixed model (CMix) [16], MRMix [18], MRAID [11], MRcML [12], GRAPPLE [13],
684 MRLASSO [17], MRRAPS [14], MRROBUST [17], and CAUSE [15]. Comparison criteria
685 included type-I error rate, power rate and estimated effect size. The statistical significance
686 was declared at the nominal level $\alpha=0.05$. In power rate estimation, only effects in the same
687 direction as the true effect were considered as potentially successful hits. Effects in the
688 opposite direction were not considered regardless of their statistical significance.

689 Because various methods may possess different type-I error rates, comparing raw
690 power rates may be unfair. To ensure a fair comparison of power rates, the raw power rate
691 was corrected by calibrating it with the type-I error rate estimated at the corresponding null

692 condition. This correction was only for comparison purpose. It allows all methods to operate
693 under the assumption of possessing a correct type-I error rate of 0.05

$$694 \quad \text{Power}_{\text{cor}} = \text{Power}_{\text{raw}} - \text{type-I} + 0.05.$$

695 CAUSE requires a substantial number of background SNPs spanning the genome to
696 estimate its model parameters. To meet this requirement, we generated an additional random
697 set of 100,000 independent SNPs that are associated with neither the exposure nor the
698 outcome. This combination of 100,000 background SNPs and the IVs was used for
699 estimating nuisance parameters (step 1), while only the IVs were used for causal inference
700 (step 2). For all other methods, only the IVs were used for causal inference.

701 Due to their high computational demands, CAUSE and MRPRESSO were assessed
702 across 200 iterations.

703 **Real data application**

704 Lean body mass is an important physiological index. Low ALM, coupled with
705 diminished muscle strength and reduced physical performance, serves as a defining criterion
706 for the onset of sarcopenia [60], which is a critical condition that can significantly impair
707 function, lead to physical disability, and is a major modifiable risk factor for frailty in older
708 adults [61, 62]. Lipids are another cluster of metabolites related to energy balance [63, 64].
709 Disorders of lipid metabolism can co-occur with the loss of skeletal muscle mass [65, 66].
710 However, the mutual relationship between ALM and lipid traits has not been well-studied.
711 Uncovering their causal relationships is thus needed to facilitate the prediction and
712 intervention of sarcopenia.

713 As a real application, we conducted a comprehensive bidirectional MR study between

714 ALM and four lipid traits, including HDL-C, LDL-C, TC, and TG using two data sources:
715 the UKB internal cohort and the summary statistics released by GLGC. The study (project
716 number 41542) was covered by general ethical approval for the UKB study, and was
717 approved by the Northwest Centre for Research Ethics Committee (11/NW/0382). All
718 participants provided informed consent.

719 The study design is displayed in **Supplemental Figure 7**. In brief, we performed both
720 the UKB-internal analysis and the UKB-GLGC joint analysis. In the UKB-internal analysis,
721 we randomly divided the entire UKB cohort into two independent sub-samples (UKB_S1
722 and UKB_S2). For each exposure-outcome pair (e.g., ALM-TC), one sub-sample served as
723 the exposure sample, while the other served as the outcome sample. This process was
724 repeated by reversing the roles of the two sub-samples so that two independent sets of
725 summary statistics were generated [41]. In the UKB-GLGC analysis, the whole UKB cohort
726 was used to generate GWAS summary statistics for ALM, while the GLGC data (excluding
727 UKB participants) provided summary statistics for the lipid traits. In total, for each
728 exposure-outcome pair, we generated three datasets that are mutually independent in
729 exposure and/or outcome, so that the results from them could cross-validate each other.

730 To evaluate the influence of sample overlap, we also applied a MR analysis in which
731 both the exposure and the outcome summary statistics were derived from the whole UKB
732 cohort, so that both samples completely overlapped.

733 The details of the analysis are described in **Supplemental Notes**. In brief, the GWAS of
734 UKB samples was performed with BOLT-LMM [67]. Genome-wide significant ($p < 5.0 \times$
735 10^{-8}) SNPs were selected from the exposure sample, followed by clumping (LD $r^2 = 0.01$

736 and window size=500 kb) to select eligible IVs using *TwoSampleMR* R package. In the
737 UKB-GLGC joint analysis, GWAS of ALM was conducted in the whole UKB cohort, while
738 the GWAS summary statistics of lipid traits were derived from the released GLGC results
739 including no UKB participants. In the UKB-overlapping analysis, the GWAS summary
740 statistics of both ALM and lipid traits were derived from the whole UKB cohort. The QC
741 and MR analysis procedure are the same across various analyses. However, in analyses
742 using UKB samples only (UKB-internal and UKB-overlapping), palindromic IVs were not
743 excluded, while in the UKB-GLGC joint analysis, palindromic IVs were excluded to avoid
744 strand orientation error.

745 **Mouse-model experiments**

746 The experimental procedures and treatments conducted in this study were ethically
747 reviewed and approved by the Animal Care Ethical Committee of Soochow University,
748 Suzhou, China, ensuring compliance with animal welfare guidelines and regulations.

749 Male C57BL/6 mice, aged 8 weeks and weighing 20 ± 5 g, were procured from
750 Shanghai Lingchang Biotechnology Co., LTD. These mice were housed in a controlled
751 environment with a temperature of 23 ± 1 °C and a 12:12-hour light-dark cycle (lights on
752 from 07:00 to 19:00), and they had free access to food and water throughout the experiment.

753 Following a 1-week acclimatization period, the mice were randomly assigned to two
754 groups: the control group ($N=12$) and the TC group ($N=12$). Standard feed was obtained
755 from Double Lion Experimental Animal Feed Technology Co., LTD, Suzhou. The control
756 group received a standard diet consisting of 71% normal diet food, 20% protein, 4% fat, and
757 5% fiber. In contrast, the TC group received a high-cholesterol diet comprising 68.3%

758 normal diet food, 1.3% cholesterol, 18.4% lard, and 12% protein. This dietary intervention
759 continued for a duration of 8 weeks.

760 Body composition analysis, including measurements of total body mass, fat mass, lean
761 mass, and fluid content, was conducted on live animals without the use of anesthesia. This
762 analysis was performed using small animal MRI equipment (Minispec LF50 body
763 composition analyzer, Bruker, Billerica, MA, USA). To conduct the measurements, each
764 mouse was placed in a specially designed plastic holder tailored for mice, without the need
765 for sedation or anesthesia. Subsequently, the holder containing the mouse was positioned
766 within the measuring space of the MRI system. To ensure the accuracy of the results,
767 measures were taken to prevent the mice from moving within the holder during the scanning
768 process. Each scan lasted approximately 2 minutes, during which the MRI equipment
769 captured detailed data on the body composition of the mice.

770 Blood biochemistry analysis was conducted using a Hitachi 7100 clinical chemistry
771 analyzer in accordance with the manufacturer's guidelines. Approximately 500 μ L of plasma
772 was collected from each mouse and transferred to a gel tube containing lithium heparin.
773 Subsequently, the plasma samples were centrifuged at 5000 rpm using a refrigerated
774 centrifuge set at 4°C for 15 minutes to obtain 160–200 μ L of serum. In cases where the
775 volume of serum obtained was insufficient for analysis, it was diluted with deionized water
776 at a ratio of 1:2 to ensure proper loading for analysis. This process ensured accurate and
777 reliable blood biochemistry measurements for each sample.

778 For each trait, the difference of measurement between the endpoint and the baseline
779 was analyzed. The comparison was made between the control group and the intervention
780 group using the Wilcoxon rank test in R package.

781 **Competing interests**

782 We declare that none of the authors have competing financial or non-financial interests.

783 **Data availability**

784 Access to UK Biobank data can be obtained by application to UK Biobank

785 (<https://www.ukbiobank.ac.uk/>).

786 **Code availability**

787 All analyses have been performed using publicly available software or custom codes.

788 PLINK (v1.90b6.5, <https://www.cog-genomics.org/plink/>) and BOLT-LMM (v2.3.2,

789 <https://alkesgroup.broadinstitute.org/BOLT-LMM/>) were used to perform association

790 analysis in the simulated data and in the UK Biobank data, respectively. The MR analyses

791 were performed using R (v4.3.2, <https://cran.r-project.org/>). The R package TwoSampleMR

792 (v0.5.7, <https://github.com/MRCIEU/TwoSampleMR>) was used to implement the IVW,

793 MREGGER, W-median, and W-mode methods. MRAID

794 (<https://github.com/yuanzhongshang/MRAID>), CAUSE (v1.2.0,

795 <https://github.com/jean997/cause>), MRcML (<https://github.com/xue-hr/MRcML/>),

796 GRAPPLE (<https://github.com/jingshuw/GRAPPLE>), MRMix

797 (<https://github.com/gqi/MRMix>), mr.raps (<https://github.com/qingyuanzhao/mr.raps>),

798 MR-PRESSO (<https://github.com/rondolab/MR-PRESSO>) were used to implement

799 respective methods. MendelianRandomization (v0.9.0,

800 <https://cran.r-project.org/web/packages/MendelianRandomization/index.html>) was used to

801 implement the CMix, MRLASSO and MRROBUST methods [68]. The R package dfoptim

802 (v2023.1.0, <https://cran.r-project.org/web/packages/dfoptim/index.html>) was used to

803 optimize high-dimensional likelihood function.

804

Figure legends

805 **Figure 1. Diagram of the proposed method.**

806 Four elements are involved: IV G , exposure X , outcome Y , and confounder U . X and Y are
807 represented by their association z-scores with G . There are three potential pathways from G
808 to Y , depending on G 's pleiotropic status: valid (purple), uncorrelated pleiotropic (blue) and
809 correlated pleiotropic (red). The causal effect Δ (green) exists in all pathways. After
810 removing the causal effect Δ from z_Y (lower panel), the residual outcome z-score z'_Y
811 contains information on pleiotropic effects only. Depending on in which pathway G is, z'_Y
812 has a pathway-specific distribution (right panel), which is used to differentiate valid and
813 pleiotropic IVs.

814 **Figure 2. The distribution of outcome z-scores at valid and pleiotropic IVs.**

815 The influence of three factors on the distribution of outcome z-score was evaluated: outcome
816 sample size ($N_Y=1e5$ or $2e5$), the variance of IV-specific heritability to the outcome (σ_h^2),
817 and the proportion of positive pleiotropic IVs ($f_p=0.5, 0.7$ or 1.0). The IV-specific
818 heritability $\sigma_{\hat{Y}}^2$ was drawn from an exponential distribution with a mean $5e-5$ or $1e-4$ so
819 that its variance $\sigma_h^2=(5e-5)^2$ or $(1e-4)^2$. The exposure sample size was set to be $N_X=2e5$. The
820 causal effect of X on Y was set to be $r=0.05$. z_Y is IV-outcome z-score. z'_Y is the residual of
821 z_Y after removing the causal effect. $\text{var}(z'_{Y,\text{theo}})$ is the theoretical variance assuming $f_p=1.0$.
822 At valid IVs, both z_Y and z'_Y conform to a standard normal distribution. At pleiotropic IVs,
823 the variance of z'_Y exceeds one and escalates with increasing N_Y and/or σ_h^2 . When $f_p=1.0$,
824 the variance of z'_Y aligns well with $\text{var}(z'_{Y,\text{theo}})$, and amplifies when $f_p<1.0$, peaking when

825 the positive and negative pleiotropic IVs are evenly balanced ($f_p=0.5$). z_Y has a similar
826 distribution to z'_Y .

827 **Figure 3. The performance of MRZ in detecting pleiotropic effects.**

828 A total of 200 IVs and 1000 iterations were simulated. **A**, The proportion of pleiotropic IVs
829 ranges from 10%-60%. The relative proportion of correlated pleiotropic IVs is 50%. The
830 power of detecting pleiotropy was declared at $\alpha = 0.05$ level. **B**, Presented is the mean
831 estimated proportion of pleiotropic IVs. Error bar is its standard deviation. Four scenarios
832 were simulated, correlated pleiotropic effects and no causal effect (correlated_null),
833 correlated pleiotropic effects and causal effect (correlated_causal), uncorrelated pleiotropic
834 effects and no causal effect (uncorrelated_null), and uncorrelated pleiotropic effects and
835 causal effect (uncorrelated_causal). **C**, In this simulation, the proportion of pleiotropic IVs
836 was fixed at 60%, while the relative proportion of correlated pleiotropic IVs ranges from
837 10%-60%. Both causal and null scenarios were simulated. Presented is the mean estimated
838 proportion of correlated pleiotropic IVs. The error bar is its standard deviation. **D**, the per-IV
839 correlated pleiotropic effect was defined as the product of the proportion of correlated
840 pleiotropic IVs and the mean correlated pleiotropic effect. The IV-specific heritability to the
841 confounder was drawn from an exponential distribution with a mean $1e-4$, $5e-5$, or 0,
842 respectively. These different settings correspond to different magnitudes of correlated
843 pleiotropic effects.

844 **Figure 4. Corrected power rate of various methods for testing causal effect.**

845 A total of 200 IVs were simulated. The sample sizes for both exposure and outcome samples

846 were 2e5. The 200 IVs explained approximately a portion of 5.8% of the exposure variance.

847 A positively dominated pleiotropic setting was simulated, in which 70% pleiotropic IVs

848 were simulated to have positive pleiotropic effects while the remaining 30% were simulated

849 to have negative pleiotropic effects. In addition, half pleiotropic IVs were simulated to be

850 correlated with the corresponding IV-exposure effects. The causal effect r was set to be 0.05

851 (positive effect) or -0.05 (negative effect). The statistical significance was declared at

852 $\alpha = 0.05$ level. Raw power rate was corrected by calibrating it with the type-I error rate

853 estimated at the corresponding null condition, using the equation

854
$$\text{Power}_{\text{cor}} = \text{Power}_{\text{raw}} - \text{type-I} + 0.05.$$

855 **Figure 5. Estimated causal effect size of various methods.**

856 The causal effect r was set to be 0.05 (positive effect) or -0.05 (negative effect). The mean

857 effect size across 1,000 iterations is presented.

858 **Figure 6. The randomized controlled experiment intervened by TC in mice.**

859 Male C57BL/6 mice were randomly allocated to control group ($N=12$) and intervention

860 group ($N=12$), followed by intervention by TC diet in the TC group for 8 weeks. For each

861 trait, the difference of measurement between the endpoint and the baseline was analyzed.

862 The comparison was made between the control group and the intervention group using the

863 Wilcoxon rank test. ***, $P < 0.001$; **, $P < 0.01$; NS, non-significant ($P > 0.05$).

864

Table 1, Performance of various methods with all valid IVs.

Method	$r=0.00$	$r=0.05$		
	Type-I error	Power	Effect	ME
MRZ	0.052	0.999	0.049	0.008
CAUSE	0.001	0.800	0.050	0.008
W-mode	0.002	0.104	0.050	0.033
MREGGER	0.049	0.950	0.049	0.011
MRMix	0.068	0.259	0.049	0.025
IVW	0.065	0.999	0.049	0.008
W-median	0.031	0.948	0.049	0.010
GRAPPLE	0.056	0.999	0.050	0.008
MRcML	0.067	0.999	0.050	0.008
RAPS	0.057	0.999	0.050	0.008
MRROBUST	0.061	0.999	0.049	0.008
MRLASSO	0.073	0.998	0.049	0.008
CMix	0.054	0.998	0.049	0.008
MRPRESSO	0.050	0.998	0.049	0.008
MRAID	0.047	0.997	0.049	0.008

865 Notes: A total of 1,000 iterations were simulated. In each iteration, the sample size for both
866 exposure and outcome samples was set to be 200,000. A total of 200 IVs were simulated, all
867 of which are valid having no pleiotropic effect on the outcome. The 200 IVs explain
868 approximately a portion of 5.8% of the exposure variance. Causal effect size was set to be
869 $r=0.00$ (null) or $r=0.05$ (causal). Effect, mean estimated effect size across the 1,000
870 iterations; ME, mean error, defined as the absolute error of the estimated effect size from the
871 true effect size $r=0.05$.

872

Table 2, Type-I error rates of various methods under pleiotropic effects.

PleiotropicIVs(%)	MRZ	CAUSE	W-mode	EGGER	MRMix	MRAID	IVW	W-median	CMix	GRAPPLE	MRcML	MRROBUST	MRLASSO	RAPS	MRPRESSO
Uncorrelated pleiotropy															
10	0.05	0.00	0.00	0.06	0.03	0.06	0.15	0.05	0.07	0.04	0.12	0.08	0.10	0.08	0.08
20	0.04	0.00	0.00	0.06	0.06	0.08	0.30	0.07	0.12	0.13	0.26	0.12	0.16	0.16	0.19
30	0.04	0.00	0.00	0.05	0.05	0.14	0.47	0.12	0.24	0.31	0.42	0.24	0.30	0.31	0.49
40	0.07	0.01	0.01	0.06	0.09	0.22	0.60	0.21	0.40	0.54	0.61	0.47	0.51	0.50	0.66
50	0.05	0.01	0.01	0.06	0.10	0.31	0.69	0.30	0.53	0.68	0.75	0.69	0.71	0.61	0.83
60	0.04	0.02	0.01	0.05	0.22	0.44	0.77	0.45	0.73	0.81	0.87	0.83	0.89	0.73	0.92
Correlated pleiotropy															
10	0.03	0.00	0.00	0.10	0.02	0.04	0.32	0.03	0.05	0.03	0.10	0.05	0.07	0.06	0.11
20	0.06	0.00	0.00	0.12	0.04	0.08	0.62	0.08	0.12	0.25	0.21	0.11	0.19	0.20	0.25
30	0.05	0.01	0.00	0.16	0.05	0.10	0.81	0.17	0.20	0.62	0.39	0.24	0.38	0.51	0.69
40	0.04	0.01	0.01	0.20	0.05	0.15	0.93	0.30	0.34	0.87	0.57	0.59	0.67	0.82	0.91
50	0.05	0.02	0.01	0.24	0.08	0.25	0.98	0.49	0.54	0.97	0.74	0.93	0.89	0.94	0.95
60	0.05	0.02	0.03	0.28	0.18	0.40	0.99	0.67	0.70	0.99	0.88	0.98	0.97	0.98	1.00

873 Notes: A total of 200 IVs and 1,000 iterations were simulated. Sample size for both exposure and outcome samples was set to be $2e5$. The 200 IVs explain
 874 approximately a portion of 5.8% of the exposure variance. In the case of uncorrelated pleiotropy, 70% of all pleiotropic IVs were randomly selected to have
 875 positive pleiotropic effects while the remaining 30% pleiotropic IVs were simulated to have negative pleiotropic effects. In the case of correlated pleiotropy,
 876 50% of pleiotropic IVs were simulated to be correlated with the corresponding IV-exposure effects. The causal effect r was set to be 0. The significance
 877 threshold was set to 0.05.

878

Table 3, Bidirectional causal effects of ALM and lipid traits identified by MRZ.

Trait	Samples	N	Forward (ALM->lipids)							Reverse (lipids->ALM)						
			IVs	R ²	F	f _{pleio}	r	SE	P	IVs	R ²	F	f _{pleio}	r	SE	P
TC	UKB_S1/UKB_S2	220K/216K	268	0.06	52.5	0.32	-0.08	0.02	3.65E-6	100	0.06	131.6	0.69	-0.05	0.04	0.22
	UKB_S2/UKB_S1	220K/216K	261	0.06	52.3	0.33	-0.08	0.02	1.01E-6	115	0.06	112.9	0.77	-0.07	0.03	0.03
	UKB/GLGC	440K/912K	716	0.09	64.3	0.61	-0.07	0.01	3.64E-7	497	0.09	175.1	0.88	-0.05	0.02	0.02
LDL-C	UKB_S1/UKB_S2	220K/216K	268	0.06	52.5	0.37	-0.05	0.02	2.67E-3	85	0.05	139.6	0.74	-0.06	0.04	0.13
	UKB_S2/UKB_S1	220K/216K	261	0.06	52.3	0.46	-0.06	0.02	3.54E-4	92	0.05	129.0	0.63	-0.06	0.03	0.05
	UKB/GLGC	440K/825K	718	0.10	64.4	0.56	-0.04	0.01	4.97E-3	397	0.08	188.8	0.66	-0.04	0.02	0.01
TG	UKB_S1/UKB_S2	220K/208K	267	0.06	52.4	0.56	0.01	0.03	0.75	109	0.05	107.6	0.66	0.03	0.02	0.15
	UKB_S2/UKB_S1	220K/209K	260	0.06	52.1	0.53	-0.02	0.02	0.33	113	0.05	103.4	1.00	-0.05	0.04	0.28
	UKB/GLGC	440K/849K	715	0.09	64.3	1.00	-0.03	0.05	0.49	461	0.07	148.1	1.00	-0.04	0.03	0.23
HDL-C	UKB_S1/UKB_S2	220K/196K	268	0.06	52.5	0.71	-0.01	0.04	0.78	191	0.10	110.0	0.69	-0.03	0.02	0.21
	UKB_S2/UKB_S1	220K/196K	261	0.06	52.3	0.77	-0.03	0.04	0.46	197	0.09	103.0	0.73	-0.03	0.02	0.16
	UKB/GLGC	440K/874K	719	0.10	64.5	0.98	-0.04	0.07	0.53	565	0.09	153.4	0.85	0.02	0.02	0.49

879 Notes: The entire UKB cohort was randomly divided into two independent sub-samples (UKB_S1 and UKB_S2). For the UKB-internal analysis, the two
880 sub-samples were used as exposure and outcome samples, respectively. For the UKB-GLGC joint analysis, the entire UKB sample was used for ALM, while
881 GLGC summary statistics were used for lipid traits. For each ALM-lipid pair, three datasets were analyzed. TC, total cholesterol; LDL-C, low-density

882 lipoprotein cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; Samples, the two samples used for ALM/lipid traits; N , sample size,
883 K represents kilo; IVs, the number of IVs; R^2 , the portion of exposure variance explained by all IVs; F , F -statistic; f_{pleio} , the estimated proportion of
884 pleiotropic IVs; r , estimated causal effect; P , p-value. The significance threshold was set at 6.25×10^{-3} (0.05/8). Significant associations were marked in bold.

885

Acknowledgments

886 This research was conducted using the UK Biobank resource under application number

887 41542. Special thank was given to an anonymous reviewer whose constructive comments

888 advised us to model correlated pleiotropic effects. This study was partially supported by the

889 funding from National Natural Science Foundation of China (32170670 to YFP, 81902181 to

890 JJN), the Project of MOE Key Laboratory of Geriatric Diseases and Immunology

891 (JYN202401 to HGR), and Suzhou Basic Research Program (Medical Application Basic

892 Research) (SKY2023147 to JJN).

893

894



References










- 895 1. Smith, G.D. and S. Ebrahim, 'Mendelian randomization': can genetic epidemiology contribute to
896 understanding environmental determinants of disease? *Int J Epidemiol*, 2003. **32**(1): p. 1-22.
- 897 2. Burgess, S., et al., *Use of Mendelian randomisation to assess potential benefit of clinical*
898 *intervention*. *BMJ*, 2012. **345**: p. e7325.
- 899 3. Burgess, S., et al., *Guidelines for performing Mendelian randomization investigations: update*
900 *for summer 2023*. *Wellcome Open Res*, 2019. **4**: p. 186.
- 901 4. Yengo, L., et al., *A saturated map of common genetic variants associated with human height*.
902 *Nature*, 2022. **610**(7933): p. 704-712.
- 903 5. Solovieff, N., et al., *Pleiotropy in complex traits: challenges and strategies*. *Nat Rev Genet*, 2013.
904 **14**(7): p. 483-95.
- 905 6. Ebrahim, S. and G. Davey Smith, *Mendelian randomization: can genetic epidemiology help*
906 *redress the failures of observational epidemiology?* *Hum Genet*, 2008. **123**(1): p. 15-33.
- 907 7. Hemani, G., J. Bowden, and G. Davey Smith, *Evaluating the potential role of pleiotropy in*
908 *Mendelian randomization studies*. *Hum Mol Genet*, 2018. **27**(R2): p. R195-R208.
- 909 8. Holmes, M.V., M. Ala-Korpela, and G.D. Smith, *Mendelian randomization in cardiometabolic*
910 *disease: challenges in evaluating causality*. *Nat Rev Cardiol*, 2017. **14**(10): p. 577-590.
- 911 9. Sanderson, E., et al., *Mendelian randomization*. *Nat Rev Methods Primers*, 2022. **2**.
- 912 10. Slob, E.A.W. and S. Burgess, *A comparison of robust Mendelian randomization methods using*
913 *summary data*. *Genet Epidemiol*, 2020. **44**(4): p. 313-329.
- 914 11. Yuan, Z., et al., *Likelihood-based Mendelian randomization analysis with automated instrument*
915 *selection and horizontal pleiotropic modeling*. *Sci Adv*, 2022. **8**(9): p. eab15744.
- 916 12. Xue, H., X. Shen, and W. Pan, *Constrained maximum likelihood-based Mendelian randomization*
917 *robust to both correlated and uncorrelated pleiotropic effects*. *Am J Hum Genet*, 2021. **108**(7): p.
918 1251-1269.
- 919 13. Wang, J., et al., *Causal inference for heritable phenotypic risk factors using heterogeneous*
920 *genetic instruments*. *PLoS Genet*, 2021. **17**(6): p. e1009575.
- 921 14. Zhao, Q., et al., *Statistical Inference in two-sample summary-data Mendelian randomization*
922 *using robust adjusted profile score*. *The Annals of Statistics*, 2020. **48**(3): p. 1742-1769.
- 923 15. Morrison, J., et al., *Mendelian randomization accounting for correlated and uncorrelated*
924 *pleiotropic effects using genome-wide summary statistics*. *Nat Genet*, 2020. **52**(7): p. 740-747.
- 925 16. Burgess, S., et al., *A robust and efficient method for Mendelian randomization with hundreds of*
926 *genetic variants*. *Nat Commun*, 2020. **11**(1): p. 376.
- 927 17. Rees, J.M.B., et al., *Robust methods in Mendelian randomization via penalization of*
928 *heterogeneous causal estimates*. *PLoS One*, 2019. **14**(9): p. e0222362.
- 929 18. Qi, G. and N. Chatterjee, *Mendelian randomization analysis using mixture models for robust and*
930 *efficient estimation of causal effects*. *Nat Commun*, 2019. **10**(1): p. 1941.
- 931 19. Verbanck, M., et al., *Detection of widespread horizontal pleiotropy in causal relationships*
932 *inferred from Mendelian randomization between complex traits and diseases*. *Nat Genet*, 2018. **50**(5):
933 p. 693-698.
- 934 20. Hartwig, F.P., G. Davey Smith, and J. Bowden, *Robust inference in summary data Mendelian*
935 *randomization via the zero modal pleiotropy assumption*. *Int J Epidemiol*, 2017. **46**(6): p. 1985-1998.
- 936 21. Bowden, J., et al., *Consistent Estimation in Mendelian Randomization with Some Invalid*





- 937 *Instruments Using a Weighted Median Estimator*. *Genet Epidemiol*, 2016. **40**(4): p. 304-14.
- 938 22. Bowden, J., G. Davey Smith, and S. Burgess, *Mendelian randomization with invalid instruments:*
939 *effect estimation and bias detection through Egger regression*. *Int J Epidemiol*, 2015. **44**(2): p.
940 512-25.
- 941 23. Burgess, S., A. Butterworth, and S.G. Thompson, *Mendelian randomization analysis with*
942 *multiple genetic variants using summarized data*. *Genet Epidemiol*, 2013. **37**(7): p. 658-65.
- 943 24. Jiang, L., et al., *Constrained instruments and their application to Mendelian randomization with*
944 *pleiotropy*. *Genet Epidemiol*, 2019. **43**(4): p. 373-401.
- 945 25. Cho, Y., et al., *Exploiting horizontal pleiotropy to search for causal pathways within a Mendelian*
946 *randomization framework*. *Nat Commun*, 2020. **11**(1): p. 1010.
- 947 26. Sanderson, E., et al., *An examination of multivariable Mendelian randomization in the*
948 *single-sample and two-sample summary data settings*. *Int J Epidemiol*, 2019. **48**(3): p. 713-727.
- 949 27. Burgess, S. and S.G. Thompson, *Multivariable Mendelian randomization: the use of pleiotropic*
950 *genetic variants to estimate causal effects*. *Am J Epidemiol*, 2015. **181**(4): p. 251-60.
- 951 28. Zhu, Z., et al., *Causal associations between risk factors and common diseases inferred from*
952 *GWAS summary data*. *Nat Commun*, 2018. **9**(1): p. 224.
- 953 29. Bowden, J., et al., *Improving the accuracy of two-sample summary-data Mendelian*
954 *randomization: moving beyond the NOME assumption*. *Int J Epidemiol*, 2019. **48**(3): p. 728-742.
- 955 30. Foley, C.N., et al., *MR-Clust: clustering of genetic variants in Mendelian randomization with*
956 *similar causal estimates*. *Bioinformatics*, 2021. **37**(4): p. 531-541.
- 957 31. Berzuini, C., et al., *A Bayesian approach to Mendelian randomization with multiple pleiotropic*
958 *variants*. *Biostatistics*, 2020. **21**(1): p. 86-101.
- 959 32. Xu, S., W.K. Fung, and Z. Liu, *MRCIP: a robust Mendelian randomization method accounting for*
960 *correlated and idiosyncratic pleiotropy*. *Brief Bioinform*, 2021. **22**(5).
- 961 33. Cheng, Q., et al., *MR-LDP: a two-sample Mendelian randomization for GWAS summary statistics*
962 *accounting for linkage disequilibrium and horizontal pleiotropy*. *NAR Genom Bioinform*, 2020. **2**(2): p.
963 lqaa028.
- 964 34. Zhu, X., et al., *An iterative approach to detect pleiotropy and perform Mendelian Randomization*
965 *analysis using GWAS summary statistics*. *Bioinformatics*, 2021. **37**(10): p. 1390-1400.
- 966 35. Grant, A.J. and S. Burgess, *An efficient and robust approach to Mendelian randomization with*
967 *measured pleiotropic effects in a high-dimensional setting*. *Biostatistics*, 2022. **23**(2): p. 609-625.
- 968 36. Howey, R., et al., *Bayesian network analysis incorporating genetic anchors complements*
969 *conventional Mendelian randomization approaches for exploratory analysis of causal relationships in*
970 *complex data*. *PLoS Genet*, 2020. **16**(3): p. e1008198.
- 971 37. Long, D., Q. Zhao, and Y. Chen, *A latent mixture model for heterogeneous causal mechanisms in*
972 *Mendelian randomization*. *The Annals of Applied Statistics*, 2024. **18**(2): p. 966-990.
- 973 38. Graham, S.E., et al., *The power of genetic diversity in genome-wide association studies of lipids*.
974 *Nature*, 2021. **600**(7890): p. 675-679.
- 975 39. Burgess, S. and S.G. Thompson, *Interpreting findings from Mendelian randomization using the*
976 *MR-Egger method*. *Eur J Epidemiol*, 2017. **32**(5): p. 377-389.
- 977 40. Zhang, L., et al., *A new method for estimating effect size distribution and heritability from*
978 *genome-wide association summary results*. *Hum Genet*, 2016. **135**(2): p. 171-84.
- 979 41. Denault, W.R.P., et al., *Cross-fitted instrument: A blueprint for one-sample Mendelian*
980 *randomization*. *PLoS Comput Biol*, 2022. **18**(8): p. e1010268.

- 981 42. Watanabe, K., et al., *A global overview of pleiotropy and genetic architecture in complex traits.*
982 *Nat Genet*, 2019. **51**(9): p. 1339-1348.
- 983 43. Frontera, W.R. and J. Ochala, *Skeletal muscle: a brief review of structure and function.* *Calcif*
984 *Tissue Int*, 2015. **96**(3): p. 183-95.
- 985 44. Zurlo, F., et al., *Skeletal muscle metabolism is a major determinant of resting energy expenditure.*
986 *J Clin Invest*, 1990. **86**(5): p. 1423-7.
- 987 45. Havel, P.J., *Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid*
988 *metabolism.* *Diabetes*, 2004. **53 Suppl 1**: p. S143-51.
- 989 46. Vella, C.A., et al., *Skeletal muscle area and density are associated with lipid and lipoprotein*
990 *cholesterol levels: The Multi-Ethnic Study of Atherosclerosis.* *J Clin Lipidol*, 2020. **14**(1): p. 143-153.
- 991 47. Pickrell, J.K., et al., *Detection and interpretation of shared genetic influences on 42 human traits.*
992 *Nat Genet*, 2016. **48**(7): p. 709-17.
- 993 48. Luke, A. and D.A. Schoeller, *Basal metabolic rate, fat-free mass, and body cell mass during*
994 *energy restriction.* *Metabolism*, 1992. **41**(4): p. 450-6.
- 995 49. Johnstone, A.M., et al., *Factors influencing variation in basal metabolic rate include fat-free*
996 *mass, fat mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine.* *Am J*
997 *Clin Nutr*, 2005. **82**(5): p. 941-8.
- 998 50. Merz, K.E. and D.C. Thurmond, *Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake.*
999 *Compr Physiol*, 2020. **10**(3): p. 785-809.
- 1000 51. Hirano, T., *Pathophysiology of Diabetic Dyslipidemia.* *J Atheroscler Thromb*, 2018. **25**(9): p.
1001 771-782.
- 1002 52. Welc, S.S. and T.L. Clanton, *The regulation of interleukin-6 implicates skeletal muscle as an*
1003 *integrative stress sensor and endocrine organ.* *Exp Physiol*, 2013. **98**(2): p. 359-71.
- 1004 53. Brenmoehl, J., et al., *Irisin is elevated in skeletal muscle and serum of mice immediately after*
1005 *acute exercise.* *Int J Biol Sci*, 2014. **10**(3): p. 338-49.
- 1006 54. Nakagomi, A., et al., *Relationships between the serum cholesterol levels, production of*
1007 *monocyte proinflammatory cytokines and long-term prognosis in patients with chronic heart failure.*
1008 *Intern Med*, 2014. **53**(21): p. 2415-24.
- 1009 55. Hardardottir, I., C. Grunfeld, and K.R. Feingold, *Effects of endotoxin and cytokines on lipid*
1010 *metabolism.* *Curr Opin Lipidol*, 1994. **5**(3): p. 207-15.
- 1011 56. Burgess, S., N.M. Davies, and S.G. Thompson, *Bias due to participant overlap in two-sample*
1012 *Mendelian randomization.* *Genet Epidemiol*, 2016. **40**(7): p. 597-608.
- 1013 57. Jiang, T., et al., *An empirical investigation into the impact of winner's curse on estimates from*
1014 *Mendelian randomization.* *Int J Epidemiol*, 2023. **52**(4): p. 1209-1219.
- 1015 58. Winkler, T.W., et al., *Quality control and conduct of genome-wide association meta-analyses.*
1016 *Nat Protoc*, 2014. **9**(5): p. 1192-212.
- 1017 59. Purcell, S., et al., *PLINK: a tool set for whole-genome association and population-based linkage*
1018 *analyses.* *Am J Hum Genet*, 2007. **81**(3): p. 559-75.
- 1019 60. Cruz-Jentoft, A.J., et al., *Sarcopenia: revised European consensus on definition and diagnosis.*
1020 *Age Ageing*, 2019. **48**(1): p. 16-31.
- 1021 61. Giles, J.T., et al., *Association of body composition with disability in rheumatoid arthritis: impact*
1022 *of appendicular fat and lean tissue mass.* *Arthritis Rheum*, 2008. **59**(10): p. 1407-15.
- 1023 62. Janssen, I., S.B. Heymsfield, and R. Ross, *Low relative skeletal muscle mass (sarcopenia) in older*
1024 *persons is associated with functional impairment and physical disability.* *J Am Geriatr Soc*, 2002.


- 1025 50(5): p. 889-96.
- 1026 63. Arner, P., et al., *Dynamics of human adipose lipid turnover in health and metabolic disease*.
1027 Nature, 2011. **478**(7367): p. 110-3.
- 1028 64. Arner, P., et al., *Adipose lipid turnover and long-term changes in body weight*. Nat Med, 2019.
1029 **25**(9): p. 1385-1389.
- 1030 65. Jiang, Y., et al., *The association of lipid metabolism and sarcopenia among older patients: a*
1031 *cross-sectional study*. Sci Rep, 2023. **13**(1): p. 17538.
- 1032 66. Kim, G. and J.H. Kim, *Impact of Skeletal Muscle Mass on Metabolic Health*. Endocrinol Metab
1033 (Seoul), 2020. **35**(1): p. 1-6.
- 1034 67. Loh, P.R., et al., *Efficient Bayesian mixed-model analysis increases association power in large*
1035 *cohorts*. Nat Genet, 2015. **47**(3): p. 284-90.
- 1036 68. Yavorska, O.O. and S. Burgess, *MendelianRandomization: an R package for performing*
1037 *Mendelian randomization analyses using summarized data*. Int J Epidemiol, 2017. **46**(6): p.
1038 1734-1739.
- 1039









Positive causal effect



Negative causal effect



Lipid traits



Body compositions

